Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Lantheus Holdings
(NQ:
LNTH
)
106.47
+1.66 (+1.58%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Lantheus Holdings
< Previous
1
2
3
Next >
Can Mid-Cap Lantheus Continue its 2022 Outperformance?
October 28, 2022
Mid-cap Lantheus Holdings has been on a revenue growth spurt boosted by a new product called Pylarify, which helps detect prostate cancer in an imaging test.
Via
MarketBeat
Topics
ETFs
Initial Public Offering
Exposures
Securities Market
Lantheus to Host Third Quarter 2022 Earnings Conference Call and Webcast on November 3, 2022, at 8:00 a.m. Eastern Time
October 20, 2022
From
Lantheus Holdings, Inc.
Via
GlobeNewswire
Lantheus Presentations at the European Association of Nuclear Medicine Annual Meeting Showcased Artificial Intelligence Data
October 17, 2022
From
Lantheus Holdings, Inc.
Via
GlobeNewswire
Lantheus Announces the First and Only FDA Cleared AI-Enabled PSMA Digital Application, aPROMISE™, Strengthening Lantheus’ Leadership in Prostate Cancer
July 29, 2021
From
Lantheus Holdings, Inc.
Via
Business Wire
Lantheus Holdings, Inc. Reports Second Quarter 2021 Financial Results
July 28, 2021
From
Lantheus Holdings, Inc.
Via
Business Wire
Lantheus Holdings to Host Second Quarter 2021 Earnings Conference Call and Webcast on July 28, 2021 at 8:00 a.m. Eastern Time
July 14, 2021
From
Lantheus Holdings, Inc.
Via
Business Wire
Lantheus To Present Piflufolastat F 18 Data at the Virtual Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2021 Annual Meeting
June 14, 2021
From
Lantheus Holdings, Inc.
Via
Business Wire
Lantheus Receives U.S. FDA Approval of PYLARIFY® (piflufolastat F 18) Injection, the First and Only Commercially Available PSMA PET Imaging Agent for Prostate Cancer
May 27, 2021
From
Lantheus Holdings, Inc.
Via
Business Wire
Lantheus Holdings Announces Presentation Featuring 18F-DCFPyL PET/CT, its PSMA-Targeted Prostate Cancer Imaging Agent at the 2021 ASCO Annual Meeting
May 21, 2021
From
Lantheus Holdings, Inc.
Via
Business Wire
Lantheus Holdings to Present at the Jefferies Virtual Healthcare Conference
May 20, 2021
From
Lantheus Holdings, Inc.
Via
Business Wire
Lantheus Holdings, Inc. Reports First Quarter 2021 Financial Results
May 04, 2021
From
Lantheus Holdings, Inc.
Via
Business Wire
EXINI Diagnostics AB, a Lantheus Company, Receives CE Mark Clearance for aPROMISE in Europe
May 03, 2021
From
Lantheus Holdings, Inc.
Via
Business Wire
Lantheus Grants Allegheny Health Network Exclusive Rights for the Use of its Microbubbles in Combination with Ultrasound Assisted Gene Therapy for the Development of a Proposed Treatment for Xerostomia
April 30, 2021
From
Lantheus Holdings, Inc.
Via
Business Wire
Lantheus Holdings to Host First Quarter 2021 Earnings Conference Call and Webcast on May 4, 2021 at 8:00 a.m. Eastern Time
April 20, 2021
From
Lantheus Holdings, Inc.
Via
Business Wire
Lantheus Expands R&D Leadership Team with Key New Hires
April 07, 2021
From
Lantheus Holdings, Inc.
Via
Business Wire
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.